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Abstract
 
Thymic selection depends on positive and negative selective mechanisms based on the avidity
of T cell interaction with antigen–major histocompatibility complex complexes. However, pe-
ripheral mechanisms for the recruitment and clonal expansion of the responding T cell reper-
toire remain obscure. Here we provide evidence for an avidity-based model of peripheral T
cell clonal expansion in response to antigenic challenge. We have used the encephalitogenic,
 
H-2 A
 
u
 
-restricted, acetylated NH
 
2
 
-terminal nonameric peptide (Ac1-9) epitope from myelin
basic protein as our model antigen. Peptide analogues were generated that varied in antigenic
strength (as assessed by in vitro assay) based on differences in their binding affinity for A
 
u
 
. In
vivo, these analogues elicited distinct repertoires of T cells that displayed marked differences in
antigen sensitivity. Immunization with the weakest (wild-type) antigen expanded the high af-
finity T cells required to induce encephalomyelitis. In contrast, immunization with strongly
antigenic analogues led to the elimination of T cells bearing high affinity T cell receptors by
apoptosis, thereby preventing disease development. Moreover, the T cell repertoire was consis-
tently tuned to respond to the immunizing antigen with the same activation threshold. This
tuning mechanism provides a peripheral control against the expansion of autoreactive T cells
and has implications for immunotherapy and vaccine design.
Key words: T cells • repertoire selection • autoimmunity • encephalomyelitis • apoptosis
 
Introduction
 
The repertoire of T lymphocytes responding to a given an-
tigen is shaped by selection during thymic development
coupled with homeostatic mechanisms active in the pe-
riphery (1). It is clear that the fate of a developing T cell
(clonal deletion or maturation to become part of the pe-
ripheral T cell pool) is determined by its sensitivity for pep-
tide antigens encountered in the thymus (1–4). However,
peripheral homeostasis and selection are only now begin-
ning to be explored (5–11). It has been suggested that a de-
gree of T cell cross-reactivity is necessary to maintain an
immune system with sufficient flexibility to adapt to a con-
tinuously changing antigenic environment (12). Therefore,
it would follow that a single antigenic epitope will have the
potential to stimulate a heterogeneous population of T cells
that expresses diverse TCRs and responds with a range of
antigen sensitivities. What is not known is the sensitivity
that a T cell must display to form part of a productive im-
mune response. To address this issue, we have investigated
how clonal expansion during an immune response is influ-
enced by the strength of antigenic challenge.
 
The acetylated NH
 
2
 
-terminal nonameric peptide (Ac1-9)
 
of myelin basic protein (MBP)
 
1
 
 is an immunodominant
T cell epitope in mice expressing the A
 
u
 
 MHC class II re-
striction element (13, 14). Remarkably, this peptide forms
highly unstable complexes with A
 
u
 
 such that a binding af-
finity cannot be determined (15, 16). Nevertheless, immu-
nization with either the Ac1-9 peptide or intact myelin can
efficiently activate Ac1-9–reactive T cells and induce ex-
perimental autoimmune encephalomyelitis (EAE [13, 17]).
We can assume, therefore, that the expanded T cells must
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Abbreviations used in this paper:
 
 7-AAD, 7-amino actinomycin D; CFSE,
carboxyfluorescein diacetate succinimidyl ester; EAE, experimental au-
toimmune encephalomyelitis; MBP, myelin basic protein; PLNC, primed
lymph node cell; TCL, T cell line.
 2
 
Tuning the T Cell Response
 
be highly sensitive for the A
 
u
 
–Ac1-9 complex to compen-
sate for such poor affinity for MHC.
The Ac1-9 peptide binds A
 
u
 
 through the interaction of
residues 4Lys and 5Arg with the peptide binding groove
(17–19). Mutational analyses coupled with modeling stud-
ies indicate that 4Lys interacts unfavorably with a hydro-
phobic pocket within the A
 
u
 
 binding cleft resulting in an
unstable interaction (20–22). Peptide analogues in which
4Lys is altered to a hydrophobic residue show greatly en-
hanced affinity for A
 
u
 
 (16, 17, 23).
We have used the Ac1-9 system to assess how the
strength of the antigenic stimulus influences T cell clonal
expansion in vivo. Peptide analogues displaying a hierarchy
of affinities for A
 
u
 
 were thus created: Ac1-9(4Tyr) 
 
. 
 
Ac1-
9(4Val) 
 
. 
 
Ac1-9(4Ala) 
 
.. 
 
Ac1-9(4Lys). These analogues
were used to compare both antigenic and immunogenic
properties of the peptide antigens. Previous studies had
demonstrated the direct correlation between affinity for A
 
u
 
and the capacity of the peptides to induce a secondary T
cell response in vitro (antigenicity). Here we demonstrate
conversely that the capacity of the peptides to induce EAE
(pathogenicity) correlates inversely with their affinity for
MHC. This is explained by the fact that strongly antigenic
peptides induce cell death among highly sensitive Ac1-9–
reactive T cells and simultaneously recruit cells with low
affinity TCRs. Based on these findings, we propose an
avidity-based model for tuning of the peripheral immune
response that allows productive expansion of T cells with a
defined sensitivity for the priming antigen.
 
Materials and Methods
 
Mice, Antigens, and Immunizations.
 
B10.PL (H-2
 
u
 
), B10.PL
 
3
 
SJL (H-2
 
uxs
 
), and Tg4 transgenic mice were bred at the School of
Medical Sciences, Bristol University. The Tg4 mouse is trans-
genic for a V
 
a
 
4/V
 
b
 
8.2 TCR specific for MBP(Ac1-9; reference
2) and was backcrossed onto the B10.PL genetic background.
Synthetic peptides based on the sequence of murine MBP
Ac1-9 (Ac-ASQKRPSQR) were prepared as described previ-
ously (24) using an ABIMED AMS 422 multiple peptide synthe-
sizer. Analogue peptides with the wild-type Lys at position 4 be-
ing altered to Ala, Val, or Tyr were used. Two peptide panels
containing Ala substitutions at individual residues were also pre-
pared. One panel contained wild-type Lys at position 4, and the
other panel also used the 4Ala substitution. Binding affinities of
peptides for purified I-A
 
u
 
 were assessed using a competitive bind-
ing assay as described previously (24).
Mice were immunized subcutaneously with 200 nmol of pep-
tide emulsified in 100 
 
m
 
l CFA supplemented with 400 
 
m
 
g 
 
Myco-
bacterium tuberculosis
 
 H37RA (Difco). For induction of EAE, mice
also received 200 ng pertussis toxin (Speywood Pharmaceuticals)
intraperitoneally on the day of immunization and 2 d later. Clini-
cal signs of EAE were assessed for 35 d after immunization.
 
Generation of Antigen-specific T Cell Lines and Hybridomas.
 
Draining lymph nodes were removed 10 d after immunization
and stimulated in vitro with 10 
 
m
 
M of the immunizing peptide
for 3 d. To generate T cell hybridomas, blasts were fused with the
TCR-deficient thymoma BW5147 as described previously (25) at
this point. The generation of the Ac1-9–reactive T cell lines
(TCLs) 4Kuxs.TCL and the Tg4.TCL has been described previ-
 
ously (24). TCLs were also generated from peptide-primed mice
by expansion of blasts subsequent to maintenance through con-
tinuous cycles of restimulation with the immunizing peptide and
expansion with T cell growth factors, as described previously
(24). All TCLs were CD4
 
1
 
 and A
 
u
 
 restricted. Activation of TCLs
was assessed using 72-h proliferation assays in 96-well microtitre
plates (2 
 
3
 
 10
 
4
 
 T cells/well) using irradiated B10.PL splenocytes
(3 
 
3
 
 10
 
5
 
/well) as APCs. Results are expressed as 
 
3
 
H-TdR incor-
poration (mean cpm of triplicate cultures). Activation of T cell
hybridomas was assessed as IL-2 secretion in response to antigen
presented by the A
 
u
 
-expressing B cell hybridoma PL8 (26). Pro-
liferation of the IL-2–dependent cell line CTLL-2 was used as a
measure of IL-2 levels in hybridoma supernatants. TCLs and hy-
bridomas were maintained and assayed in IMDM supplemented
with 2 mM 
 
L
 
-glutamine, 5 
 
3
 
 10
 
-5
 
M 2-ME, 100 U/ml penicillin,
100 
 
m
 
g/ml streptomycin (all from GIBCO BRL/Life Technolo-
gies), and 5% FCS (Sigma-Aldrich). For analysis of primed lymph
node cell (PLNC) proliferative responses (10 d after immuniza-
tion), 3 
 
3
 
 10
 
5
 
 cells/well were cultured for 72 h using X-VIVO
15 serum-free medium (BioWhittaker) supplemented with 2 mM
 
l
 
-glutamine (GIBCO BRL) and 10
 
2
 
5 
 
M 2-ME.
 
Tg4 Transgenic T Cell Transfer Experiments.
 
Tg4 transgenic
splenic T cells were purified using a nylon wool adherence nega-
tive selection step. These T cell–enriched populations (
 
.
 
80%
CD4
 
1
 
) were labeled with carboxyfluorescein diacetate succini-
midyl ester (CFSE; Molecular Probes) as described previously (27)
and 5 
 
3
 
 10
 
6
 
 cells injected intravenously into nontransgenic litter-
mates. 1 d after transfer, mice were immunized with either Ac1-9,
Ac1-9(4Tyr), or CFA alone as described above. 5 d later, draining
lymph node cells were removed and CFSE
 
1
 
 cells assessed for ap-
optosis by staining with 7-amino actinomycin D (7-AAD) and
PE-conjugated annexin V (BD PharMingen) as per manufac-
turer’s instructions.
 
Analysis of A
 
u
 
–Ac1-11(4Tyr) Tetramer Staining of TCLs.
 
The
generation of a soluble construct of A
 
u
 
 linked to the Ac1-11
(4Tyr) peptide is described elsewhere (28). Tetrameric complexes
were prepared by incubation with PE-conjugated streptavidin
and used to stain TCLs by incubation at 4
 
8
 
C for 3 h. Analysis of
staining was performed using a FACScan™ (Becton Dickinson)
and the CELLQuest™ (Becton Dickinson) and WinMDI 2.8
analysis software (Scripps Research Institute; http://facs.scripps.
edu). Kinetics of loss of tetramer staining were assessed using the
previously described method (29). In brief, after incubation of
TCLs with tetramer, cells were washed twice and suspended in
PBS containing 100 
 
m
 
g/ml of the A
 
u
 
-binding monoclonal anti-
body 10-2-16 to prevent tetramer rebinding and incubated for
various time points at 4
 
8
 
C before analysis of tetramer staining.
Results were expressed as total fluorescence within each popula-
tion as a percentage of that found before incubation with 10-2-16.
Receptor expression by TCLs was assessed using FITC-conju-
gated anti-TCR (H57-597; BD PharMingen) or anti-CD4
(H129.19; Sigma-Aldrich).
 
Results
 
Enhanced Antigenicity Correlates Inversely with Induction of
Autoimmunity.
 
To study the influence of the strength of
antigenic stimulus on selection of the T cell repertoire, we
required a well-defined model system in which precise al-
terations in peptide sequence confer marked differences in
antigenic properties in vitro. The MBP(Ac1-9) model has
been shown previously to fulfill these criteria (17, 23).
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For this study, we selected Ac1-9 analogue peptides in
which the wild-type 4Lys was substituted with either Ala,
Val, or Tyr. Results from competitive binding assays con-
firmed previous reports that these analogues showed greatly
enhanced binding to the A
 
u
 
 MHC class II molecule (Table
I [16, 17, 23]). The 4Tyr peptide proved to be the stron-
gest binder with an affinity at least 5 logs higher than wild-
type Ac1-9. The 4Val peptide showed slightly weaker
binding than 4Tyr, whereas the 4Ala peptide showed inter-
mediate binding (
 
.
 
1,000-fold stronger than wild-type, but
100-fold weaker than 4Tyr).
 
These differences in MHC binding translated directly
into antigenic activity in vitro. We generated TCL specific
for the wild-type Ac1-9(4Lys) peptide from three different
sources. Two TCLs were derived from H-2
 
uxs
 
 mice immu-
nized with either intact myelin (4Kuxs.TCL) or the 4Lys
peptide (4Lys.TCL). The third TCL was derived using
splenocytes taken from an unprimed Tg4 transgenic mouse
(this mouse expresses an Ac1-9–specific TCR derived from
PL/J mice immunized with rat MBP [2]). Each of these
three TCLs was maintained by in vitro restimulation with
the wild-type 4Lys peptide. These Ac1-9–specific TCLs
were tested for proliferative responses to 4Lys and the three
analogue peptides (Fig. 1, A–C). Each TCL showed the
same response profile, with responses to wild-type 4Lys ev-
ident at a concentration of 10 nM. The three analogue
peptides all showed “superagonist” activity, with 4Tyr and
4Val capable of inducing responses at femtomolar (fM)
concentrations. The response to 4Ala was lost below 100
fM, consistent with the intermediate A
 
u
 
 binding displayed
by this peptide.
Given the increased antigenic activity in vitro of the su-
peragonist peptides, one might predict that these peptides
would be powerful inducers of EAE in vivo. However, this
was not the case. Whereas immunization with wild-type
4Lys induced EAE in 60% of mice, disease was observed
rarely using the intermediate 4Ala analogue and not at all
with the strongest superagonists 4Val and 4Tyr (Table I,
and Fig. 1, D and E). These findings indicated that the ef-
 
Table I.
 
A
 
u
 
 Binding Affinity Correlates Inversely with
EAE Induction
 
Peptide Sequence
Relative binding
affinity for A
 
u
 
Incidence of
EAE
 
%
 
4Lys
 
AcASQKRPSQR
 
,
 
0.00001 60
4Ala
 
AcASQARPSQR
 
0.01 10
4Val
 
AcASQVRPSQR
 
0.2 0
4Tyr
 
AcASQYRPSQR
 
1 0
Binding affinities of peptides for A
 
u
 
 were assessed as described previously
(reference 24). Incidence of EAE represents cumulative data from
experiments shown in Fig. 1, D and E.
Figure 1. Ac1-9 position 4 analogues behave as superag-
onists in vitro, but show markedly reduced encephalitoge-
nic activity in vivo. (A–C) TCLs generated against wild-
type Ac1-9 were tested for proliferative responses to Ac1-9
and position 4 analogue peptides. Mice were immunized
to induce EAE as described in Materials and Methods. Re-
sults represent two identical experiments, one using
B10.PL mice (D) and the other using B10.PL3SJL mice
(E). In each experiment five mice were used per group.
The incidence of EAE induced with 4Lys was 3/5 in each
experiment.
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fect of increasing antigenic strength in vivo was to reduce
the immunogenicity of the peptides, correlating with a re-
duction in the productive activation of pathogenic T cells.
The markedly reduced encephalitogenic activity of the
4Ala peptide has been reported previously (17). These stud-
ies also reported deficits in T cell activation at the primed
lymph node level, and it was therefore assumed that the
4Ala peptide was non (or weakly) immunogenic (17, 30).
 
The Immune Response Tunes T Cell Reactivity to a Predeter-
mined Threshold of Sensitivity.
 
To clarify the immunogenic
potential of our analogue peptides, mice were immunized
with each of the four peptides individually and the draining
lymph node cells were restimulated in vitro with the same
peptide used for priming. Using this approach, we were
able to derive TCLs specific for each peptide (4Lys.TCL,
4Ala.TCL, 4Val.TCL, and 4Tyr.TCL). Analysis of each of
these TCLs showed striking differences in antigen sensitiv-
ity (Fig. 2). First, stimulation with the wild-type 4Lys pep-
tide revealed that the 4Lys.TCL responded normally and
was activated by a dose of 10 nM. However, the TCLs
primed against the superagonists were far less sensitive to
stimulation with the wild-type peptide (Fig. 2 A). The an-
tigenic hierarchy described above was reversed such that
priming with the 4Ala peptide induced T cells that re-
sponded to 4Lys at 1 
 
m
 
M, whereas 100 
 
m
 
M was required
to stimulate the 4Tyr.TCL. Therefore, it seems likely that
the superagonist peptides failed to induce EAE in vivo be-
cause they were unable to expand T cells of sufficient sensi-
tivity to respond to wild-type Ac1-9 in the central nervous
system.
Most strikingly, analysis of the response of the individual
TCL to peptides against which they were raised revealed
identical dose response patterns. In each case, the TCL
would respond at a dose of 1–10 nM (Fig. 2 B). These
findings indicate that, as an immune response develops in
vivo, an active mechanism tunes the T cell population that
is expanded to have a predetermined sensitivity for antigen.
One possible explanation for the insensitivity of superag-
onist-primed T cells to the wild-type 4Lys peptide would
be that they recognize distinct amino acids as TCR contact
residues. Previous reports had identified MHC and TCR
contact residues within the Ac1-9 sequence (17–19). In ad-
dition to position 4, position 5 Arg also contacts A
 
u
 
, with
the 5Ala analogue showing reduced affinity for A
 
u
 
 and fail-
ing to stimulate Ac1-9–specific T cells. In contrast, Ala
substitutions at positions 3 and 6 were shown to abrogate T
cell activation without influencing A
 
u
 
 binding.
Figure 2. T cell activation thresholds are tuned to the strength of anti-
genic challenge. The response to Ac1-9 (A) and the response to immu-
nizing antigen (B) are shown. TCLs were generated from mice immu-
nized with either wild-type Ac1-9 (4Lys) or position 4 analogue peptides
by in vitro stimulation of PLNCs with the immunizing peptide. TCLs
were cultured with varying doses of 4Lys (A) or the immunizing peptide
relevant to each TCL (B). Symbols refer to the peptide against which the
TCL was generated: 4Lys (r), 4Ala (n), 4Val (s), or 4Tyr (h). These
priming and in vitro restimulation protocols were used in three indepen-
dent experiments that yielded consistent results.
Figure 3. TCLs specific for either wild-type Ac1-9 or superagonist
recognize the same TCR contact residues. TCLs were stimulated with
two panels of Ac1-9 analogues with Ala substitutions at individual resi-
dues. One panel was based on wild-type (4Lys) Ac1-9, the other panel
also incorporated a 4Ala substitution. Parentheses in legends refer to these
panels (i.e., the amino acid used at position 4). The 1Ala peptides repre-
sent the wild-type sequence (Ala occurs naturally at this residue). Re-
sponses were tested over a dose range of peptide (10 mM shown).
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TCR contact residues for the various cell lines described
above were assessed by measuring response profiles of TCLs
using two panels of peptide analogues containing Ala sub-
stitutions at individual peptide residues. One peptide panel
contained wild-type Lys at position 4, and the second panel
also possessed the 4Ala substitution. This was necessary, as
superagonist-primed TCLs were insensitive to the wild-
type 4Lys peptide but all responded to the 4Ala analogue.
We used the Tg4.TCL and 4Lys.TCL to represent the
“normal” T cell repertoire. We found that both of these
TCLs failed to respond to the 3Ala, 5Ala, and 6Ala pep-
tides, and that this was also the case whether position 4 was
Lys or Ala (Fig. 3). This confirms previous observations
(17–19) and indicates that the 4Ala analogue must form a
similar conformation to that of wild-type 4Lys within the
groove of A
 
u
 
. We also tested the 4Ala.TCL and 4Tyr.TCL
for responses to the Ala-substituted analogues that also con-
tained 4Ala, and observed an identical response pattern
with the 3Ala, 5Ala, and 6Ala analogues being nonstimula-
tory (Fig. 3). The 4Tyr.TCL also failed to respond to 3Ala
and 6Ala analogues that contained the 4Tyr substitution
(data not shown). Taken together, these data indicate that
there was no significant qualitative deviation of TCR rec-
ognition caused by alterations at position 4, with all TCLs
tested focusing on positions 3 and 6 as TCR contacts.
We then addressed the question of whether tuning of
the cell lines had occurred in vivo or was a result of re-
 
peated in vitro stimulation with antigen. T cell hybridomas
generated directly from PLNC populations were tested for
response patterns to the priming antigen and wild-type
peptide (Table II). Again we observed that hybridomas
from mice primed with superagonists were increasingly in-
sensitive to 4Lys and responded to the priming antigen at
concentrations generally within the 1–100 nM range. Fur-
thermore, analysis of proliferative responses of PLNC from
mice immunized with either 4Lys or 4Tyr showed evi-
dence of tuning (Fig. 4). Although the 4Tyr peptide be-
haved as a superagonist after priming with 4Lys, the re-
sponse after priming with 4Tyr was equivalent to that seen
to 4Lys after priming with 4Lys. From these data we con-
clude that the tuning event occurred during the develop-
ment of immunity in vivo and was not the result of contin-
ued exposure to antigen in vitro.
Two possible mechanisms could account for the tuning
of T cell sensitivity: (a) biochemical detuning of the signal-
ing machinery within a homogeneous Ac1-9–specific rep-
ertoire, or (b) the selective expansion of distinct repertoires
of T cells in response to the different peptides. No differ-
ences in antigen receptor expression levels between the dif-
ferent panels of hybridomas were evident (serological anal-
ysis of TCR-
 
a
 
/
 
b
 
 and CD4 expression; data not shown).
Thus, lack of sensitivity could not be attributed to reduced
TCR availability. The response to wild-type Ac1-9 has
been reported to be dominated by T cells expressing TCR
using V
 
b
 
8 variable region gene products (31). Serological
analysis confirmed this for the 4Lys-induced hybridomas
(11 of 12 V
 
b
 
8
 
1
 
) whereas the superagonist-primed hybrid-
 
Table II.
 
Superagonist Peptides Select T Cells with Reduced 
Antigen Sensitivity In Vivo
 
Priming
peptide 4Lys 4Ala 4Val 4Tyr
In vitro
peptide 4Lys 4Tyr 4Lys 4Ala 4Lys 4Val 4Lys 4Tyr
 
m
 
M
 
0.00001 6
0.0001 6 1
0.001 1 2
0.01 3 4 5 6
0.1 8 2 1 7 8
1 1 1 1 2 3
10 3 4 3
100 2 5 7
No response 3 7
Total 12 6 14 19
Peptide-specific T cell hybridomas were generated from PLNCs as
described in Materials and Methods and tested for responsiveness to
peptide analogs over a range of concentrations. The minimal stimulatory
dose of each peptide is shown in terms of the number of hybridomas
beginning to respond at each concentration. Note that 0.00001 
 
m
 
M was
the lowest concentration used in these experiments. Therefore, the six
4Lys hybridomas responding at this concentration of 4Tyr may have
been more sensitive than these results reveal.
Figure 4. Tuning of T cell responsiveness is evident at the primed
lymph node level. PLNCs were isolated from B10.PL3SJL mice immu-
nized with either the 4Lys or 4Tyr peptides. PLNCs were tested for pro-
liferative responses to dose ranges of each peptide. Data are from one of
three experiments which gave consistent results.
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omas tended not to use Vb8 (4Ala, 1 of 6; 4Val, 0 of 14;
4Tyr, 0 of 16 tested). These findings rule out the possibility
that superagonist-primed T cells were simply Ac1-9–spe-
cific T cells that had been desensitized. Rather, they imply
that tuning of the immune response depends on expansion
of distinct T cell repertoires.
Tuning Results from TCR Affinity–based Selection of T Cells
with Permitted Sensitivity for Antigen. Based on our results,
we propose an avidity model of T cell clonal expansion in
which those cells with sensitivity to antigenic challenge
above a certain threshold are purged from the productive
immune response. Irrespective of the signal given by the
priming antigen, the resulting immune response will be
tuned to fall within a window of sensitivity by selecting
distinct repertoires of T cells for expansion. To test the
avidity model, we addressed the fate of highly sensitive
Ac1-9–reactive T cells in mice primed with the high affin-
ity 4Tyr analogue. T cells from the Tg4 mouse are highly
sensitive to 4Tyr stimulation in vitro (2; Fig. 1 B). T cells
were isolated from naive Tg4 spleen, labeled with CFSE,
and transferred into nontransgenic littermates. In prelimi-
nary experiments to assess the incorporation of the trans-
ferred cells in lymphoid organs, spleens isolated from recip-
ient mice 2 d after cell transfer contained z1% CFSE1 cells
(Fig. 5 B).
In further experiments, recipient mice were immunized
with either 4Lys, 4Tyr, or adjuvant alone 1 d after cell
transfer. Significant numbers of CFSE1 cells could not be
detected in popliteal lymph nodes taken 5 d after priming
with CFA alone (Fig. 5 C). Therefore, in this system the
presence of antigen was required for the accumulation of
antigen-specific T cells in the nodes. In the absence of anti-
gen (CFA alone), antigen-specific cells presumably either
do not home to these lymph nodes or their frequency is di-
minished to a level below detection, due to the accumula-
tion and expansion of cells specific for antigens in CFA. In
contrast, discrete but heterogeneous populations of CFSE1
cells were identified in the draining popliteal and inguinal
lymph nodes of mice primed with antigen. Fig. 5 C shows
the CFSE1 population present after immunizaton with
4Lys. Populations staining with this low level of CFSE
were consistently found whether priming with either 4Lys
or 4Tyr. This weak level of CFSE label compared with the
levels shown in Fig. 5 B corresponds with the gated cells
having undergone three to five rounds of division in re-
sponse to immunization. As this gate was used for both the
4Lys- and 4Tyr-primed populations, the superagonist did
not cause a noticeably more rapid proliferation of the trans-
ferred cells. These CFSE1 cells ranged from 1.5 to 3.4% of
4Lys-PLNCs and 1.2 to 3.1% of 4Tyr-PLNCs. Counter-
staining with annexin V and 7-AAD revealed that after
priming with 4Tyr, .70% of CFSE1 cells were showing
signs of early apoptosis (annexin V1, 7-AAD2) compared
with ,10% after priming with 4Lys (Fig. 5 D). Therefore,
Ac1-9–sensitive T cells were deleted after exposure to the
4Tyr superagonist in vivo.
The next outstanding question was how cells that were
selected after immunization with strongly antigenic ligands
avoided deletion. The relative insensitivity of T cells ex-
panded after challenge with superagonist was not due to
expression of reduced levels of TCR or CD4 (Fig. 6, A
and B). An alternative explanation was that cells escape de-
letion through expression of low affinity TCRs. Measure-
ment of the relative affinity of TCR expressed by indi-
vidual T cells has been made possible through the
development of soluble MHC class II–peptide complexes
(29, 32, 33). Tetrameric complexes of Au–Ac1-11(4Tyr)
(28) were used to stain TCLs generated against 4Lys or
4Tyr and to assess the affinity of their TCRs. These com-
plexes reacted specifically with Ac1-9–reactive T cells, as
no staining was observed when using splenic T cells from
unimmunized B10.PL mice or short-term T cell popula-
tions expanded against purified protein derivative of Myco-
bacterium tuberculosis (28). Analysis of tetramer staining pat-
terns (Fig. 6 C) revealed a homogeneous population of
Tg4.TCL (expressing a single TCR). However, the
4Lys.TCL displayed a broader pattern of staining, indicat-
ing a heterogeneous population using a range of TCRs
with varying affinities for the tetrameric complex. This
pattern is similar to those described in other systems using
tetramers to stain TCRs specific for foreign antigens (29,
Figure 5. In vivo activation with superagonist results in apoptotic re-
moval of highly sensitive Ac1-9–reactive T cells. CFSE-labeled Tg4
transgenic T cells were transferred to nontransgenic littermates. Presence
of CFSE1 cells was assessed in spleens of nontransferred mice (A) versus
recipient mice 2 d after cell transfer (B). (C) Presence of CFSE-labeled T
cells in primed lymph nodes 5 d after immunization with Ac1-9(4Lys) or
CFA alone. Similar CFSE1 populations to those after 4Lys priming were
also evident after priming with Ac1-9(4Tyr). The percentage of CFSE1
cells ranged between 1.5 and 3.4% for 4Lys-PLNCs and 1.2 and 3.1% for
4Tyr-PLNCs. (D) Annexin V–PE staining of 4Lys versus 4Tyr PLNC
populations after gating on CFSE1 cells. 8% of the 4Tyr-primed, CFSE/
annexin V double-positive population also stained with 7-AAD. Data
represent results from individual mice. Consistent results were obtained
with a total of eight mice per group over three separate experiments.
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32). In contrast, the 4Tyr.TCL stained weakly with tet-
ramer, indicating a more homogeneous population ex-
pressing only TCRs of low affinity. In further experiments
we assessed the rate of dissociation of the tetramers once
loaded to each TCL (Fig. 6 D). The less sensitive
4Tyr.TCL showed more rapid loss of tetramer staining
than either 4Lys.TCL or Tg4.TCL. Immunization with
the superagonist therefore led to the expansion of T cells
expressing TCRs with lower affinity for peptide–MHC
than those raised against the wild-type antigen.
Discussion
The notion of avidity-based tuning of T cell reactivity as
a mechanism for central tolerance is well rehearsed (3, 34–
36). Indeed, the absence of endogenous MBP in the shiv-
erer mouse has been reported to allow T cells with speci-
ficity for high affinity MHC binding peptides to escape
thymic negative selection (37, 38). This is the first study to
address the influence of the strength of the antigenic stimu-
lus on peripheral T cell repertoire selection during the ini-
tiation of an immune response. The results reveal an inher-
ent tuning event involving selective expansion of T cells to
maintain antigen reactivity within a consistent threshold of
sensitivity. This threshold, between 1 and 10 nM, is not re-
stricted to the MBP(Ac1-9) system, as other TCLs gener-
ated in our laboratory (reactive against self- or foreign
antigens) also display this characteristic. Furthermore, a re-
markable number of reports describe similar thresholds for
CD41 T cell activation (39–44). In this study, we have al-
tered the strength of the antigenic signal by manipulation
of the peptide sequence so as to vary the affinity for MHC
class II and hence antigenicity. Quantitative variations in
the antigenic signal may also be achieved by manipulation
of other parameters, such as duration of exposure and anti-
gen dose (33).
Although our study addresses how the strength of signal
affects repertoire selection against a single immunodomi-
nant epitope, other factors will also influence repertoire se-
lection against complex antigens. First, efficiency of antigen
processing and MHC–peptide complex formation has an
important bearing on immunodominance (45). Determi-
nant capture (45) can influence epitope selection involving
either single or distinct MHC loci (46, 47). Once formed,
the relative abundance of MHC–peptide complexes is not
the sole factor governing immunodominance (48). Indeed,
studies of immune recognition of virus have reported
highly abundant MHC–peptide complexes against which T
cell reactivity could not be found (49, 50). This may be
due to deletion via clonal exhaustion (51) or a tuning
mechanism due to excessive antigenic stimulus, as de-
scribed here. Clearly, such deletional effects will influence
subsequent responses on encounter of the same or a cross-
reactive antigen. There is also evidence that the presence of
T cells recognizing one epitope can inhibit T cell expan-
sion against other epitopes during an immune response
(48). The tuning mechanism will therefore serve as a check
on T cell sensitivity as part of a multiparameter selection
process.
Our findings indicate that, at least in our system, tuning
is a deletional event based on the affinity of TCR for the
peptide–MHC complex. When T cells bearing high affin-
ity TCRs receive a powerful antigenic stimulus in vivo
(i.e., “normal” Ac1-9–reactive T cells primed with 4Tyr)
they rapidly progress to the contraction phase of the re-
sponse and are removed by apoptosis. The T cells ex-
panded after priming with superagonist express lower affin-
ity TCRs, and this compensates for the strong antigenic
stimulus to maintain antigen reactivity within the permit-
ted sensitivity range. This mechanism is consistent with a
recent report that T cells with low affinity TCRs are se-
lected by prolonged exposure to high doses of foreign anti-
gen (33).
Our use of tetrameric 4Tyr–Au complexes to assess TCR
affinity revealed a continuous range of affinities from low
to high after immunization with the wild-type 4Lys pep-
tide, (Fig. 6 C). This was in contrast with the homoge-
neous populations found with the Tg4.TCL (expressing a
single transgenic TCR and therefore having a fixed affinity)
and the 4Tyr.TCL, which expressed only low affinity
TCRs. The survival of low affinity T cells in the 4Lys.TCL
population indicates that these cells were fully capable of
sustained expansion in response to antigen in vitro. This
may reflect survival due to the in vitro conditions such as
excess production of IL-2 by the high affinity T cells also
Figure 6. Immunization with the 4Tyr superagonist leads to preferen-
tial expansion of T cells expressing TCRs with low affinity for Ac1-9.
The 4Lys.TCL, 4Tyr.TCL, and Tg4.TCL were stained with TCR-a/b
(A), CD4 (B), or Au–Ac1-11(4Tyr) tetrameric complexes (C). Each plot
shows unstained 4Lys.TCL cells. (D) After tetramer staining, cells were
washed and incubated for varying times. Results are expressed as the lev-
els of total tetramer staining in each population as a percentage of the
level of staining before incubation.
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present in these cultures. An earlier study has indicated that
such low affinity cells become increasingly rare as the dose
of antigen used to stimulate polyclonal populations in vitro
is reduced (33). Therefore, it is difficult to extrapolate to
the possible survival of such low affinity T cells in vivo.
However, the presence of low affinity cells does suggest
that in this system the dominant factor influencing the rep-
ertoire during in vivo expansion is the loss of high affinity
cells through deletion (when immunizing with the 4Tyr
superagonist) rather than the loss of low affinity cells
through insufficient strength of antigenic signal (when im-
munizing with wild-type 4Lys).
Recent reports of selective tolerance to a foreign antigen
also provide evidence of a tuning mechanism. A wild-type
peptide from moth cytochrome c was able to induce effec-
tive tolerance to itself, but subsequent immunization with a
superagonist analogue led to expansion of a distinct T cell
population bearing lower affinity TCRs (43, 44). Prelimi-
nary experiments indicate that T cells primed to 4Lys in
vivo, and transgenic Tg4 T cells, initially proliferate and
then undergo apoptosis after in vitro exposure to superago-
nist peptides (data not shown). Removal by apoptosis of T
cells that have been overstimulated by antigen has been
proposed as a major homeostatic mechanism in maintaining
the immune repertoire (52). Our studies support this no-
tion of “propriocidal” control and suggest that strength of
antigenic signal may be as important as duration of expo-
sure to antigen. Although our findings suggest that T cell
sensitivity is largely controlled by TCR affinity, other fac-
tors such as level of expression of TCR (40) or CD4 (53),
or rewiring of T cell signaling machinery (42, 54, 55),
might also play a role in other situations.
Superagonist-induced apoptosis in mice transgenic for
Ac1-9–specific TCRs has been reported previously by our-
selves and others (41, 56, 57). A deletional mechanism is
consistent with previous reports that the 4Ala superagonist
inhibits EAE in nontransgenic mice but does not induce a
suppressive T cell population (protection cannot be trans-
ferred with T cells [17, 30]). Similar deletional effects have
also been used to inhibit EAE by use of a superagonist vari-
ant peptide based on a different MBP T cell epitope (58).
Several studies have reported induction of T cell apoptosis
after administration of high doses of antigen in tolerogenic
form (39, 58, 59). The results of this study underline the
notion that deletion can occur during an active peripheral
immune response and that this is dependent on the sensi-
tivity of the T cell for antigen such that only relatively in-
sensitive T cells are allowed to expand. Furthermore, this
study is the first to show that the net result of the balance
between apoptosis and expansion is that the resulting T cell
repertoire will consistently respond to the initiating antigen
within a narrow dose–response window.
What would be the immunological benefit of restricting
productive CD41 T cell immunity to a predetermined
threshold of sensitivity? The 4Tyr superagonist was found
to induce clonal deletion of Tg4 T cells both during thy-
mic development when given in soluble form (2) and dur-
ing an active peripheral immune response (this study).
Therefore, both immature and mature T cells are sensitive
to apoptosis induced with the same antigenic signal. A pe-
ripheral fail-safe mechanism of clonal deletion would re-
move any potentially autoaggressive T cells that escape
central tolerance. This would serve to limit the risk of au-
toimmune disorders developing via molecular mimicry (60,
61). We found that immunization with superagonist (lead-
ing to hyporesponsiveness to Ac1-9) fails to effectively in-
duce EAE. Therefore, priming for a pathogenic autoreac-
tive response requires the stimulus derived from the
eliciting antigen to fall within a limited range. Thus, only T
cells capable of responding to both foreign and self-antigens
with the permitted sensitivity would be pathogenic. Highly
self-reactive T cells would be removed by thymic selection,
while those that escape would be further purged through
activation by superagonist foreign ligands during peripheral
immune responses. A recent description that immunization
with a peptide derived from human papillomavirus 7 led to
EAE included findings relevant to this point (62). Low
doses of viral peptide were found to activate T cells cross-
reactive with an epitope within the 87–99 sequence of
MBP and to elicit EAE. However, high doses of the viral
peptide led to expansion of viral-specific T cells that failed
either to cross-react with MBP or induce EAE. Loss of self-
reactivity through the tuning of the T cell response to the
stronger foreign antigenic challenge would account for
these findings.
Activation-induced cell death is believed to serve as a
counterbalance designed to avoid excessive T cell expan-
sion (52) and prevent autoimmunity (63, 64). Keeping the
threshold for CD41 T cell activation above a defined point
ensures that the response is focused on sites of high ligand
density, for example antigen-specific B cells requiring T
cell help. The immune system therefore concentrates lim-
ited resources at sites of greatest impact.
The proposed avidity model of clonal expansion has im-
portant implications. First, it argues that susceptibility to
avidity-based elimination is intrinsic to the T cell through-
out its lifespan and is not restricted to thymocyte develop-
ment. Second, superagonists should evidently be more ef-
fective treatments for silencing autoimmunity (56, 58, 65).
Finally, these findings argue against the use of superagonists
for vaccine design. Such an approach would inevitably lead
to the removal of the highly antigen-sensitive T cells that
would be most effective in combating infection.
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